THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, February 24, 2021
Today’s pharmaceutical companies need advanced supply chain opportunities to optimize drugs development, which has resulted in a lot of firms seeking partnerships with CDMOs.
FREMONT, CA: As the population ages and healthcare standards continue to increase, pharmaceutical products' demand has been increasing across the world. With these market trends of increased demand, contract development and manufacturing organizations meet new expectations from customers. The pharma sector has been exploding, with mergers and acquisitions, layoffs, and outsourcing operations becoming occurrences among its firms' network. This will translate into a sustainable sector. The perpetual absence of new products has been one of the significant problems in the pharma sector, and mergers and acquisitions seem to be one of the best ways for increasing efficiency in the discovery and development of new drugs.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Today, the CDMOs are on the upswing, and over the last few years, the sector has increased and is now considered a vital piece of drug development for most pharmaceutical firms. All pharma players are presently adopting outsourcing strategies as one of the essential ways to increase their pipelines and timelines for new products. CDMOs are also accelerating leveraging for biotechnology firms to further widen their development and manufacturing potentials, offering solutions that are fully integrated with their pre-existing services.
The CDMO sector is a very fragmented space. In comparison to the CRO industry, in which leading companies own 70 percent. However, this is a change as more mergers and acquisitions take place across the CDMO market, with consolidation expected in few years. This is in line with several pharmaceutical firms; more customers are opting to outsource to one full-service CDMO rather than many niche providers, as this optimized the supply chain and can mitigate time to market. As the CDMO market continues to evolve, pharmaceutical firms will have more opportunities to further their pipelines in the upcoming years.
More in News